HER-2 (Human epidermal growth factor receptor 2)

P=N/A, N=15, Active, not recruiting, Parul Barry | Recruiting --> Active, not recruiting | Trial completion date: Mar 2028 --> Jan 2030 | Trial primary completion date: Apr 2026 --> Jan 2026

P=N/A, N=50, Recruiting, University of Aberdeen | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P3, N=376, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial primary completion date: Mar 2026 --> Dec 2026

P2, N=35, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Jul 2027

In this real-world cohort of HER2-positive breast cancer patients, baseline HFA-ICOS stratification showed limited ability to clearly distinguish cardiotoxicity risk across categories. These findings suggest that baseline risk assessment alone may be insufficient for individualized prediction and should be complemented by dynamic, on-treatment surveillance strategies.

In addition, we highlight the importance of molecular stratification and biomarker-driven approaches to identify patients most likely to benefit from anti-angiogenic therapy. Overall, while VEGFR-targeted therapy alone has shown limited success, rational combination strategies and improved patient selection may significantly enhance its clinical utility in TNBC.

Integration with synNotch receptors and chimeric antigen receptors (CARs) further allows dual-input regulation of downstream responses, including gene expression, cytokine release, and cytotoxicity. Together, these results establish extrabody as a versatile and generalizable interface for externally controlled cellular communication and synthetic signaling.

Furthermore, we detail how GnT-V orchestrates the epithelial-mesenchymal transition (EMT) and cytoskeletal remodeling via the RhoA/Rac1 axis. By integrating these signaling networks with the enzyme's regulatory environment, we provide a comprehensive roadmap of GnT-V pathogenesis and propose that targeting the GnT-V/GnT-III balance represents a promising strategy for precise cancer diagnosis and therapy.

She underwent a combinatorial protocol at ChemoThermia Oncology Center (Istanbul, Turkey) comprising of Metabolically Supported Chemotherapy (MSCT) consisting of docetaxel, doxorubicin, and cyclophosphamide administered following a 14-hour fast and low dose insulin-induced mild hypoglycemia, alongside a strict ketogenic diet (GKI < 2.0). Adjunctive therapies included local and whole-body hyperthermia, hyperbaric oxygen therapy (HBOT), and a combination of repurposed drugs (metformin, aspirin, doxycycline, mebendazole, ivermectin, and famotidine) designed to target metabolic, inflammatory, and survival pathways...A durable response in a patient with otherwise poor prognosis was achieved after systematically targeting cancer cell bioenergetics and the tumor microenvironment. These findings support further clinical investigation into multimodal metabolic therapies for advanced HR+ breast cancer.

These findings enable risk stratification before trastuzumab initiation. Future research should validate a predictive model incorporating these factors and assess cardioprotective strategies, thereby translating risk assessment into actionable protocols to optimize cardiac safety without compromising oncologic outcomes.

Specifically, tumors with HER2 2+ expression exhibited a smaller median diameter, while the classic histological subtype was predominantly observed in HER2 0/1+ tumors. These associations indicate that differential HER2 expression may delineate distinct pathological phenotypes of bladder urothelial carcinoma.

Concurrently, dysregulated signaling, such as the Wnt/β-catenin pathway, inhibits dendritic cell maturation and recruits Myeloid-Derived Suppressor Cells (MDSCs) and regulatory T cells (Tregs) into the tumor microenvironment, thereby blunting the anti-tumor T cell response. This review examines the role of key pluripotency regulators in TNBC-mediated immune evasion, highlighting emerging immunotherapeutic strategies targeting these networks and summarizing current clinical research.